Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

BACKGROUND: Afatinib has shown favorable response rates (RRs) and longer progression free survival (PFS) in lung cancer patients harboring EGFR mutations compared with standard platinum-based chemotherapy. However, serious adverse drug reactions (ADRs) limit the clinical application of afatinib. MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Chen, Yi-Chieh, Tsai, Ming-Ju, Lee, Mei-Hsuan, Kuo, Chia-Yu, Shen, Mei-Chiou, Tsai, Ying-Ming, Chen, Huang-Chi, Hung, Jen-Yu, Huang, Ming-Shyan, Chong, Inn-Wen, Yang, Chih-Jen
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8091516/
https://ncbi.nlm.nih.gov/pubmed/33941115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08235-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados